North America Cancer Therapy Market Insights Forecasts to 2033

• The North America Cancer Therapy Market Size was valued at USD 3.13 Billion in 2023.
• The Market Size is Growing at a CAGR of 8.3% from 2023 to 2033
• The North America Cancer Therapy Market Size is Expected to Reach USD 6.95 Billion by 2033

The North America Cancer Therapy Market Size is Anticipated to Reach USD 6.95 Billion by 2033, Growing at a CAGR of 8.3% from 2023 to 2033

Market Overview

Cancer therapy refers to a wide range of therapies and strategies used to treat cancer and prevent it from spreading. Cancer treatment aims to destroy cancer cells, limit their growth, or alleviate symptoms of the disease. Cancer treatments are generally classified into several types, which are frequently used in combination to achieve positive results. Several factors influence therapy selection, including the type and stage of cancer, a patient's overall health, and specific cancer cell properties. The North America cancer therapy market is expanding rapidly, owing to increasing evidence of cancer on a large scale, which is raising awareness and creating a growing demand for cancer therapies. Government and non-governmental organizations (NGOs) are increasing awareness campaigns, creating demand for anti-cancer medicines and therapies. Ongoing advances in medical research, genomics, and technology have resulted in the identification of new cancer targets as well as the development of more precise and targeted therapies, thereby improving treatment efficacy.

Report Coverage

This research report categorizes for the North America cancer therapy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America cancer therapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America cancer therapy market.

Driving Factors

As the number of cancer cases increases worldwide, more patients want to be diagnosed and treated. The increasing demand for cancer treatment directly drives market growth. The diversity of cancer types and subtypes necessitates a wide range of treatment options. The increasing prevalence of various cancer types necessitates the development of new therapies, which fosters innovation and market growth. Personalized medicine has grown in popularity as we gain more knowledge about cancer at the molecular and genetic levels. Targeted therapies are becoming more common as the importance of personalized treatments grows. Immunotherapy has emerged as a groundbreaking cancer treatment modality. The increasing prevalence of cancer has sparked a growing interest among researchers in developing immunotherapeutic interventions, resulting in the expansion of this market segment.

Restraining Factors

The lack of important cancer medications may cause patient access issues. Some patients in certain regions or with specific types of cancer may face barriers to accessing necessary treatments that improve their chances of receiving quality care.

Market Segmentation

The North America cancer therapy market share is classified into therapy type and cancer type

• The chemotherapy segment is expected to hold the largest market share through the forecast period.

The North America cancer therapy market is segmented by therapy type into chemotherapy, radiation therapy, hormonal therapy, targeted therapy, and others. Among these, the chemotherapy segment is expected to hold the largest market share through the forecast period. While chemotherapy has limitations and potential side effects, it does provide several advantages in cancer treatment. Chemotherapy can be used as an adjuvant therapy, following primary treatments such as surgery or radiation. This helps to eliminate any remaining cancer cells and lowers the risk of cancer recurrence. Chemotherapy is used to treat a variety of cancers, including leukemia, lymphoma, breast cancer, and lung cancer, among others. Its versatility makes it an important part of cancer treatment.

• The breast cancer segment is expected to dominate the North America cancer therapy market during the forecast period.       

Based on the cancer type, the North America cancer therapy market is divided into breast cancer, lung cancer, prostate cancer, blood cancer, and others. Among these, the breast cancer segment is expected to dominate the North America cancer therapy market during the forecast period. Breast cancer is often treated with a combination of therapies, such as surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. The type of breast cancer, its stage, hormone receptor status, HER2 status, and the patient's overall health all influence treatment decisions.                                                                     

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America cancer therapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Johnson and Johnson
• AstraZeneca PLC
• Merck & Co. Inc.
• Bayer AG
• Amgen Inc
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc
• Bristol Myers Squibb Company
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In September 2022, Eli Lilly and Company announced that the United States Food and Drug Administration (FDA) has approved Retevmo (selpercatinib, 40 mg, and 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

Market Segment

This study forecasts revenue at North America, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the North America cancer therapy market based on the below-mentioned segments:

North America Cancer Therapy Market, By Therapy Type

• Chemotherapy
• Radiation Therapy
• Hormonal Therapy
• Targeted Therapy
• Others

North America Cancer Therapy Market, By Cancer Type

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Blood Cancer
• Others